ArticleEvolutionary applications2020
When, why and how tumour clonal diversity predicts survival.
Article in Evolutionary applications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Fluctuating DNA methylation sites encode colorectal tumour growth history.bioRxiv : the preprint server for biology · 2026Article
- Selective sweep probabilities in spatially expanding populations.Nature communications · 2026Article
- Lynch syndrome-associated and sporadic microsatellite unstable colorectal cancers: different patterns of clonal evolution yield highly similar tumours.Human molecular genetics · 2024Article
- A seven-step guide to spatial, agent-based modelling of tumour evolution.Evolutionary applications · 2024Review
- Article
- Cell Adaptive Fitness and Cancer Evolutionary Dynamics.Cancer informatics · 2023Article
- Heterogeneity of the tumor immune microenvironment and its clinical relevance.Experimental hematology & oncology · 2022Review
- Forward to a methodological proposal to support cancer patients: the dialogics' contribution for the precision care.Medical oncology (Northwood, London, England) · 2022Article
- Spatial structure governs the mode of tumour evolution.Nature ecology & evolution · 2022Article
- Spatial structure impacts adaptive therapy by shaping intra-tumoral competition.Communications medicine · 2022Article
- Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study.Nature ecology & evolution · 2022Article
- Paracrine Behaviors Arbitrate Parasite-Like Interactions Between Tumor Subclones.Frontiers in ecology and evolution · 2021Article
- Genetic and non-genetic clonal diversity in cancer evolution.Nature reviews. Cancer · 2021Review
- When, why and how tumour clonal diversity predicts survival.Evolutionary applications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The utility of intratumour heterogeneity as a prognostic biomarker is the subject of ongoing clinical investigation. However, the relationship between this marker and its clinical impact is mediated by an evolutionary process that is not well understood. Here, we employ a spatial computational model of tumour evolution to assess when, why and how intratumour heterogeneity can be used to forecast tumour growth rate and progression-free survival. We identify three conditions that can lead to a positive correlation between clonal diversity and subsequent growth rate: diversity is measured early in tumour development; selective sweeps are rare; and/or tumours vary in the rate at which they acquire driver mutations. Opposite conditions typically lead to negative correlation. In cohorts of tumours with diverse evolutionary parameters, we find that clonal diversity is a reliable predictor of both growth rate and progression-free survival. We thus offer explanations-grounded in evolutionary theory-for empirical findings in various cancers, including survival analyses reported in the recent TRACERx Renal study of clear-cell renal cell carcinoma. Our work informs the search for new prognostic biomarkers and contributes to the development of predictive oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.